

L Number	Hits	Search Text	DB	Time stamp
1	0	cell adj1 line near5 gene adj1 expression adj1 test adj1 compound	USPAT; US-PGPUB; DERWENT	2003/03/18 10:45
3	4129	cell adj1 line and gene adj1 expression and test adj1 compound	USPAT; US-PGPUB; DERWENT	2003/03/18 10:46
2	7	cell adj1 line and gene adj1 expression adj1 test adj1 compound	USPAT; US-PGPUB; DERWENT	2003/03/18 10:47
4	2441	(cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma	USPAT; US-PGPUB; DERWENT	2003/03/18 10:48
5	0	leukamia and ((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma)	USPAT; US-PGPUB; DERWENT	2003/03/18 10:48
6	389528	((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and pattren or profile	USPAT; US-PGPUB; DERWENT	2003/03/18 10:48
7	1590	((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and (((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and pattren or profile)	USPAT; US-PGPUB; DERWENT	2003/03/18 10:49
8	1484	((((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and (((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and pattren or profile)) and cell adj1 type	USPAT; US-PGPUB; DERWENT	2003/03/18 10:49
9	917	(((((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and ((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and pattren or profile)) and cell adj1 type) and alteration	USPAT; US-PGPUB; DERWENT	2003/03/18 10:52
10	917	(((((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and ((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and pattren or profile)) and cell adj1 type) and alteration) and function	USPAT; US-PGPUB; DERWENT	2003/03/18 10:56



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books
Search PubMed <input type="text" value="for gene expression in different cells and functi"/> <input type="button" value="Go"/> <input type="button" value="Clear"/>								
Limits Preview/Index History Clipboard Details								

Display	Summary	Show: 20	Sort	Send to	Text
Items 1-15 of 15					One page.

Entrez
PubMed

- ☐ 1: Minier C, Lelong C, Djemel N, Rodet F, Tutundjian R, Favrel P, Mathieu M, Leboulenger F. [Related Articles, Links](#)
- Expression and activity of a multixenobiotic resistance system in the Pacific oyster *Crassostrea gigas*.
Mar Environ Res. 2002 Sep-Dec;54(3-5):455-9.
PMID: 12408601 [PubMed - indexed for MEDLINE]

PubMed
Services

- ☐ 2: Schwartz IF, HersHKovitz R, Iaina A, Gnessin E, Wollman Y, Chemichowski T, Blum M, Levo Y, Schwartz D. [Related Articles, Links](#)
- Garlic attenuates nitric oxide production in rat cardiac myocytes through inhibition of inducible nitric oxide synthase and the arginine transporter CAT-2 (cationic amino acid transporter-2).
Clin Sci (Lond). 2002 May;102(5):487-93.
PMID: 11980565 [PubMed - indexed for MEDLINE]









Related
Resources

- ☐ 3: Vogensen SB, Jensen HS, Stensbol TB, Frydenvang K, Bang-Andersen B, Johansen TN, Egebjerg J, Krogsgaard-Larsen P. [Related Articles, Links](#)
- Resolution, configurational assignment, and enantiopharmacology of 2-amino-3-[3-hydroxy-5-(2-methyl-2H-tetrazol-5-yl)isoxazol-4-yl]propionic acid, a potent GluR3- and GluR4-preferring AMPA receptor agonist.
Chirality. 2000 Nov;12(10):705-13.
PMID: 11054828 [PubMed - indexed for MEDLINE]

- ☐ 4: Wang Y, Ye J, Ganapathy V, Longo N. [Related Articles, Links](#)
- Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency.
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2356-60.
PMID: 10051646 [PubMed - indexed for MEDLINE]

- ☐ 5: Katiyar SK, Korman NJ, Mukhtar H, Agarwal R. [Related Articles, Links](#)
- Protective effects of silymarin against photocarcinogenesis in a mouse skin model.
J Natl Cancer Inst. 1997 Apr 16;89(8):556-66.
PMID: 9106644 [PubMed - indexed for MEDLINE]

- ☐ 6: Mehta RG, Moriarty RM, Mehta RR, Penmasta R, Lazzaro G, Constantinou A, Guo L. [Related Articles, Links](#)
- Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.
J Natl Cancer Inst. 1997 Feb 5;89(3):212-8.
PMID: 9017001 [PubMed - indexed for MEDLINE]

- ☐ **7:** Brem AS, Bina RB, Klinger JR, King T, Werner JC. Related Articles, Links
 Glucocorticoid metabolism in the newborn rat heart.
Proc Soc Exp Biol Med. 1995 Jun;209(2):146-51.
PMID: 7770464 [PubMed - indexed for MEDLINE]
- ☐ **8:** Broughton BC, Steingrimsdottir H, Weber CA, Lehmann AR. Related Articles, Links
 Mutations in the xeroderma pigmentosum group D DNA repair/transcription gene in patients with trichothiodystrophy.
Nat Genet. 1994 Jun;7(2):189-94.
PMID: 7920640 [PubMed - indexed for MEDLINE]
- ☐ **9:** Brigle KE, Spinella MJ, Westin EH, Goldman ID. Related Articles, Links
 Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells.
Biochem Pharmacol. 1994 Jan 20;47(2):337-45.
PMID: 8304978 [PubMed - indexed for MEDLINE]
- ☐ **10:** Torma H, Asselineau D, Andersson E, Martin B, Reiniche P, Chambon P, Shroot B, Darmon M, Vahlquist A. Related Articles, Links
 Biologic activities of retinoic acid and 3,4-didehydroretinoic acid in human keratinocytes are similar and correlate with receptor affinities and transactivation properties.
J Invest Dermatol. 1994 Jan;102(1):49-54.
PMID: 7507153 [PubMed - indexed for MEDLINE]
- ☐ **11:** Beck CA, Weigel NL, Edwards DP. Related Articles, Links
 Effects of hormone and cellular modulators of protein phosphorylation on transcriptional activity, DNA binding, and phosphorylation of human progesterone receptors.
Mol Endocrinol. 1992 Apr;6(4):607-20.
PMID: 1316549 [PubMed - indexed for MEDLINE]
- ☐ **12:** Shimada T, Guengerich FP. Related Articles, Links
 Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver.
Proc Natl Acad Sci U S A. 1989 Jan;86(2):462-5.
PMID: 2492107 [PubMed - indexed for MEDLINE]
- ☐ **13:** Yelton MM, Hamer JE, de Souza ER, Mullaney EJ, Timberlake WE. Related Articles, Links
 Developmental regulation of the Aspergillus nidulans trpC gene.
Proc Natl Acad Sci U S A. 1983 Dec;80(24):7576-80.
PMID: 6324178 [PubMed - indexed for MEDLINE]
- ☐ **14:** Fahmy MJ, Fahmy OG. Related Articles, Links
 Misregulation versus mutation in the alteration of gene expression by carcinogens through interactions with transposable elements in Drosophila melanogaster.
Teratog Carcinog Mutagen. 1983;3(1):27-39.
PMID: 6132455 [PubMed - indexed for MEDLINE]

☐ 15: [Hoffman-Liebermann B, Liebermann D, Sachs L.](#)

[Related Articles, Links](#)



Regulation of gene expression by tumor promoters. III. Complementation of the developmental program in myeloid leukemic cells by regulating mRNA production and mRNA translation.

Int J Cancer. 1981 Nov 15;28(5):615-20.

PMID: 6975761 [PubMed - indexed for MEDLINE]

Display	Summary	▼	Show: 20	▼	Sort	▼	Send to	Text	▼
Items 1-15 of 15									One page.

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Mar 6 2003 10:50:17

Welcome to STN International! Enter x:x

LOGINID:sssptal656sxc

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB			
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS			
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002;
			saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE)
			now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on
STN			
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS	41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS	42	Jan 29	Simultaneous left and right truncation added to COMPENDEX,

ENERGY, INSPEC
 NEWS 43 Feb 13 CANCERLIT is no longer being updated
 NEWS 44 Feb 24 METADEX enhancements
 NEWS 45 Feb 24 PCTGEN now available on STN
 NEWS 46 Feb 24 TEMA now available on STN
 NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation
 NEWS 48 Feb 26 PCTFULL now contains images
 NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
 CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
 AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:40:02 ON 18 MAR 2003

=> FIL BIOSIS MEDLINE EMBASE LIFESCI CAPLUS		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'BIOSIS' ENTERED AT 11:40:39 ON 18 MAR 2003
 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 11:40:39 ON 18 MAR 2003

FILE 'EMBASE' ENTERED AT 11:40:39 ON 18 MAR 2003
 COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'LIFESCI' ENTERED AT 11:40:39 ON 18 MAR 2003
 COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CAPLUS' ENTERED AT 11:40:39 ON 18 MAR 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s gene (w) expression (2a) test (w) compound
 3 FILES SEARCHED...
 L1 8 GENE (W) EXPRESSION (2A) TEST (W) COMPOUND

=> dup remove l1

PROCESSING COMPLETED FOR L1

L2 7 DUP REMOVE L1 (1 DUPLICATE REMOVED)

=> d l2 1-7

L2 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2003:173780 CAPLUS

TI Bioassay for screening toxins using *Saccharomyces cerevisiae* reporter gene

expression system linked to toxin-induced gene promoter

IN Iwahashi, Hitoshi; Momose, Yuko; Kitagawa, Emiko; Takahashi, Junko

PA National Institute of Advanced Industrial Science and Technology, Japan; Daikin Industries, Ltd.

SO PCT Int. Appl., 150 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003018792	A1	20030306	WO 2002-JP8495	20020823
	W: JP, US				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
PRAI	JP 2001-255379	A	20010824		

L2 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2003:29507 CAPLUS

DN 138:84442

TI Screening regulators of visceral fat accumulation by microarray gene expression profile analysis

IN Matsuki, Yasushi; Iguchi, Haruhisa

PA Sumitomo Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 34 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003009900	A2	20030114	JP 2001-198641	20010629
PRAI	JP 2001-198641		20010629		

L2 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2002:906464 CAPLUS

DN 138:1266

TI Molecular toxicology modeling by gene expression profiling in the presence

of renal toxicity markers

IN Mendrick, Donna; Porter, Mark; Johnson, Kory; Higgs, Brandon; Castle, Arthur; Elashoff, Michael

PA Gene Logic, Inc., USA

SO PCT Int. Appl., 446 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI WO 2002095000 A2 20021128 WO 2002-US16173 20020522
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-292335P P 20010522
US 2001-297523P P 20010613
US 2001-298925P P 20010619
US 2001-303807P P 20010710
US 2001-303808P P 20010710
US 2001-303810P P 20010710
US 2001-315047P P 20010828
US 2001-324928P P 20010927
US 2001-330462P P 20011022
US 2001-330867P P 20011101
US 2001-331805P P 20011121
US 2001-336144P P 20011206
US 2001-340873P P 20011219
US 2002-357842P P 20020221
US 2002-357843P P 20020221
US 2002-357844P P 20020221
US 2002-364134P P 20020315
US 2002-370144P P 20020408
US 2002-370206P P 20020408
US 2002-370247P P 20020408
US 2002-372794P P 20020417
US 2002-371679P P 20020421

L2 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2002:107604 CAPLUS

DN 136:146134

TI Molecular toxicology modeling based on global changes in gene expression
profiles and expressed nucleic acid markers for drug toxicity

IN Mendrick, Donna; Porter, Mark W.; Johnson, Kory R.; Castle, Arthur L.;
Elashoff, Michael R.

PA Gene Logic, Inc., USA

SO PCT Int. Appl., 239 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002010453	A2	20020207	WO 2001-US23872	20010730
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,				
	HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,				
	RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,				
	VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002119462	A1	20020829	US 2001-917800	20010731

PRAI US 2000-222040P P 20000731
 US 2000-244880P P 20001102
 US 2001-290029P P 20010511
 US 2001-290645P P 20010515
 US 2001-292336P P 20010522
 US 2001-295798P P 20010606
 US 2001-297457P P 20010613
 US 2001-298884P P 20010619
 US 2001-303459P P 20010709

L2 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1
 AN 2002:125899 CAPLUS
 DN 136:351414

TI Human genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

IN Lillie, James; Xu, Yongyao; Wang, Youzhen; Steinmann, Kathleen

PA Millennium Predictive Medicine, Inc., USA

SO PCT Int. Appl., 3695 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001051628	A2	20010719	WO 2001-XB798	20010110
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	WO 2001051628	A2	20010719	WO 2001-US798	20010110
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2000-176077P P 20000114
 US 2000-189167P P 20000314
 US 2000-192099P P 20000324
 US 2000-193480P P 20000329
 US 2000-205230P P 20000515
 US 2000-211315P P 20000609
 US 2000-220534P P 20000725
 WO 2001-US798 W 20010110

L2 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 1999:640973 CAPLUS

DN 131:253332

TI Method for detecting change in **gene expression** induced by **test compounds**

IN Muramatsu, Masaaki; Wakao, Hiroshi; Wakao, Rika; Yano, Kazuhiro; Noguchi, Teruhisa; Suyama, Akira

PA Helix Research Institute, Japan

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9950401	A1	19991007	WO 1999-JP1574	19990326
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRAI JP 1998-100096 19980327

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 1992:248406 CAPLUS

DN 116:248406

TI Screening assays for inhibitors of oncoprotein action

IN Brent, Roger; Golemis, Erica; Lech, Karen F.; Anderson, Catherine

PA USA

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9205286	A1	19920402	WO 1991-US6839	19910920
	W: AU, CA, CS, FI, HU, JP, KR, NO, SU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	AU 9186272	A1	19920415	AU 1991-86272	19910920
	EP 550592	A1	19930714	EP 1991-917394	19910920
	EP 550592	B1	19970115		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 06503713	T2	19940428	JP 1991-516071	19910920
	HU 66827	A2	19950130	HU 1993-822	19910920
	AT 147793	E	19970215	AT 1991-917394	19910920
	CN 1065092	A	19921007	CN 1991-110638	19910921
	ZA 9107616	A	19930924	ZA 1991-7616	19910924
	NO 9301061	A	19930521	NO 1993-1061	19930323
	US 5580721	A	19961203	US 1993-50198	19931007
PRAI	US 1990-586781		19900924		
	WO 1991-US6839		19910920		

=> s gene (w) expression and cell (w) types

3 FILES SEARCHED...

L3 20464 GENE (W) EXPRESSION AND CELL (W) TYPES

=> s l3 and test (w) compound

L4 5 L3 AND TEST (W) COMPOUND

=> dup rem l4

PROCESSING COMPLETED FOR L4

L5 3 DUP REM L4 (2 DUPLICATES REMOVED)

=> d l5 1-3

L5 ANSWER 1 OF 3 MEDLINE
 AN 2002352270 MEDLINE
 DN 22090062 PubMed ID: 12096331
 TI [Improving the embryonic stem cell test (EST) by establishing molecular endpoints of tissue specific development using murine embryonic stem cells (D3 cells)].
 Etablierung molekularer Endpunkte zur Weiterentwicklung des Embryonalen Stammzelltests (EST) mit embryonalen Stammzellen der Maus (Zelllinie D3).
 AU Seiler Andrea; Visan Anke; Pohl Ingeborg; Genschow Elke; Buesen Roland; Spielmann Horst
 CS Zentralstelle zur Erfassung und Bewertung von Ersatz- und Ergänzungsmethoden zum Tierversuch (ZEBET), Bundesinstitut für gesundheitlichen Verbraucherschutz und Veterinärmedizin (BgVV), D-Berlin, Germany.. seiler.zebet@bgvv.de
 SO ALTEX, (2002) 19 Suppl 1 55-63.
 Journal code: 100953980. ISSN: 0946-7785.
 CY Germany: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 200210
 ED Entered STN: 20020704
 Last Updated on STN: 20021008
 Entered Medline: 20021004

L5 ANSWER 2 OF 3 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE
 1
 AN 2001:501809 BIOSIS
 DN PREV200100501809
 TI Molecular markers in embryonic stem cells.
 AU zur Nieden, N. I. (1); Ruf, L. J.; Kempka, G.; Hildebrand, H.; Ahr, H. J.
 CS (1) Research Toxicology, Bayer AG, 42096, Wuppertal:
 nicole.melzer.nm.@bayer.ag.de Germany
 SO Toxicology In Vitro, (August October, 2001) Vol. 15, No. 4-5, pp. 455-461.
 print.
 ISSN: 0887-2333.
 DT Article
 LA English
 SL English

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:487431 CAPLUS
 DN 131:112381
 TI **Gene expression** fingerprint and use in compound screening for developing therapeutics
 IN Johnson, Paul H.; Ponte, Phyllis A.; Zajchowski, Deborah A.
 PA Schering Aktiengesellschaft, Germany
 SO PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9937817	A1	19990729	WO 1999-US1552	19990125
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,				

KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
 MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
 TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2317650 AA 19990729 CA 1999-2317650 19990125
 AU 9923419 A1 19990809 AU 1999-23419 19990125
 EP 1051516 A1 20001115 EP 1999-903380 19990125
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2002505852 T2 20020226 JP 2000-528723 19990125
 PRAI US 1998-13496 A2 19980126
 US 1999-236026 A 19990122
 WO 1999-US1552 W 19990125
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:40:02 ON 18 MAR 2003)

FILE 'BIOSIS, MEDLINE, EMBASE, LIFESCI, CAPLUS' ENTERED AT 11:40:39 ON
 18
 MAR 2003

L1 8 S GENE (W) EXPRESSION (2A) TEST (W) COMPOUND
 L2 7 DUP REMOVE L1 (1 DUPLICATE REMOVED)
 L3 20464 S GENE (W) EXPRESSION AND CELL (W) TYPES
 L4 5 S L3 AND TEST (W) COMPOUND
 L5 3 DUP REM L4 (2 DUPLICATES REMOVED)

=> medline

MEDLINE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
 For a list of commands available to you in the current file, enter
 "HELP COMMANDS" at an arrow prompt (=>).

=> FIL MEDLINE

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	34.88	35.09

FILE 'MEDLINE' ENTERED AT 11:48:11 ON 18 MAR 2003

FILE LAST UPDATED: 16 MAR 2003 (20030316/UP). FILE COVERS 1958 TO DATE.

On June 9, 2002, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
 MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/summ2003.html>
 for a description on changes.

This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> E POWELL THOMAS/AU 25

E1 1 POWELL TAYLOR D/AU
 E2 1 POWELL THERESA L/AU

E3	0	-->	POWELL THOMAS/AU
E4	2		POWELL THOMAS A/AU
E5	2		POWELL THREETS K/AU
E6	3		POWELL TIA/AU
E7	1		POWELL TIM/AU
E8	1		POWELL TIM D/AU
E9	3		POWELL TOM/AU
E10	59		POWELL TUCK J/AU
E11	16		POWELL V/AU
E12	1		POWELL V D JR/AU
E13	2		POWELL V I/AU
E14	1		POWELL V JR/AU
E15	2		POWELL V L/AU
E16	1		POWELL V R/AU
E17	1		POWELL VINDEN B/AU
E18	1		POWELL VIVIEN I/AU
E19	60		POWELL W/AU
E20	13		POWELL W A/AU
E21	1		POWELL W A JR/AU
E22	1		POWELL W B/AU
E23	14		POWELL W C/AU
E24	6		POWELL W D/AU
E25	4		POWELL W E/AU

=> E POWELL T/AU 25

E1	1		POWELL SUZANNE K/AU
E2	1		POWELL SUZANNE Z/AU
E3	141	-->	POWELL T/AU
E4	8		POWELL T A/AU
E5	4		POWELL T E/AU
E6	1		POWELL T E 3RD/AU
E7	4		POWELL T F/AU
E8	14		POWELL T G/AU
E9	5		POWELL T H/AU
E10	33		POWELL T J/AU
E11	7		POWELL T J JR/AU
E12	28		POWELL T L/AU
E13	2		POWELL T M/AU
E14	8		POWELL T O/AU
E15	172		POWELL T P/AU
E16	1		POWELL T R/AU
E17	1		POWELL T S/AU
E18	5		POWELL T V/AU
E19	17		POWELL T W/AU
E20	1		POWELL T W JR/AU
E21	1		POWELL T W SR/AU
E22	1		POWELL TAMMY P/AU
E23	1		POWELL TAYLOR D/AU
E24	1		POWELL THERESA L/AU
E25	2		POWELL THOMAS A/AU

=> E 25

E26	2		POWELL THREETS K/AU
E27	3		POWELL TIA/AU
E28	1		POWELL TIM/AU
E29	1		POWELL TIM D/AU
E30	3		POWELL TOM/AU
E31	59		POWELL TUCK J/AU
E32	16		POWELL V/AU
E33	1		POWELL V D JR/AU

E34	2	POWELL V I/AU
E35	1	POWELL V JR/AU
E36	2	POWELL V L/AU
E37	1	POWELL V R/AU
E38	1	POWELL VINDEN B/AU
E39	1	POWELL VIVIEN I/AU
E40	60	POWELL W/AU
E41	13	POWELL W A/AU
E42	1	POWELL W A JR/AU
E43	1	POWELL W B/AU
E44	14	POWELL W C/AU
E45	6	POWELL W D/AU
E46	4	POWELL W E/AU
E47	16	POWELL W F/AU
E48	7	POWELL W H/AU
E49	16	POWELL W J/AU
E50	79	POWELL W J JR/AU

```
=> S (E10) AND 1990<=PY<=2000
      33 "POWELL T J"/AU
      4625401 1990<=PY<=2000
L6      17 ("POWELL T J"/AU) AND 1990<=PY<=2000
```

```
=> DIS L6 1- TI
YOU HAVE REQUESTED DATA FROM 17 ANSWERS - CONTINUE? Y/(N):Y
```

```
L6 ANSWER 1 OF 17 MEDLINE
TI Chronic neurobehavioural effects of mercury poisoning on a group of Zulu
chemical workers.
```

```
L6 ANSWER 2 OF 17 MEDLINE
TI Psychiatrists' referrals to self-help groups for people with mood
disorders.
```

```
L6 ANSWER 3 OF 17 MEDLINE
TI A discrete subpopulation of dendritic cells transports apoptotic
intestinal epithelial cells to T cell areas of mesenteric lymph nodes.
```

```
L6 ANSWER 4 OF 17 MEDLINE
TI Derivation of temporary emergency exposure limits (TEELs).
```

```
L6 ANSWER 5 OF 17 MEDLINE
TI Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine
kinase inhibitors.
```

```
L6 ANSWER 6 OF 17 MEDLINE
TI Recommended default methodology for analysis of airborne exposures to
mixtures of chemicals in emergencies.
```

```
L6 ANSWER 7 OF 17 MEDLINE
TI Attitudes of AA contact persons toward group participation by persons
with
a mental illness.
```

```
L6 ANSWER 8 OF 17 MEDLINE
TI Inhibition of platelet-derived growth factor-mediated signal transduction
and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-
carboxamide.
```

```
L6 ANSWER 9 OF 17 MEDLINE
```

TI SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

L6 ANSWER 10 OF 17 MEDLINE

TI A follow-up study of patients hospitalized after minor head injury.

L6 ANSWER 11 OF 17 MEDLINE

TI A tumor-derived protein which provides T-cell costimulation through accessory cell activation.

L6 ANSWER 12 OF 17 MEDLINE

TI Ontogeny of tolerogen-responsive lymphocytes following neonatal inoculation of class II disparate semiallogeneic cells.

L6 ANSWER 13 OF 17 MEDLINE

TI The secreted tumor-associated antigen 90K is a potent immune stimulator.

L6 ANSWER 14 OF 17 MEDLINE

TI Self-help research and the public mental health system.

L6 ANSWER 15 OF 17 MEDLINE

TI In vitro suppression of cytotoxic T cell generation by lymphocytes from mice rendered neonatally tolerant of class II MHC alloantigens.

L6 ANSWER 16 OF 17 MEDLINE

TI Influence of I-E expression on induction of neonatal transplantation tolerance.

L6 ANSWER 17 OF 17 MEDLINE

TI I-E molecules and I-E-reactive T cells play a central role in neonatal H-2 tolerance.

=> DIS L6 1-10 IBIB ABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.10 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 1 OF 17 MEDLINE

ACCESSION NUMBER: 2000478714 MEDLINE

DOCUMENT NUMBER: 20483371 PubMed ID: 11030454

TITLE: Chronic neurobehavioural effects of mercury poisoning on a group of Zulu chemical workers.

AUTHOR: Powell T J

CORPORATE SOURCE: West Berkshire Priority Care Services, NHS Trust, Reading, UK.. trevor@wbpcs-tr.anglox.nhs.uk

SOURCE: BRAIN INJURY, (2000 Sep) 14 (9) 797-814.
Journal code: 8710358. ISSN: 0269-9052.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200102

ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20010215

AB PRIMARY OBJECTIVE: To assess the nature and severity of reported neurobehavioural symptoms of mercury poisoning, in a group of Zulu chemical workers (n = 16), employed by a mercury processing plant, exposed

to neurotoxic levels of mercury, 5 years after exposure. RESEARCH DESIGN: A group-control design was adopted, where the exposed group was matched for age, sex, race, occupational and educational background. METHOD/PROCEDURES: Both groups were administered a specially selected battery of psychometric tests to measure neuropsychological functioning. OUTCOME AND RESULTS: The exposed group had significantly impaired short term verbal and spatial memory, impaired sustained and divided attention, and impaired motor speed. They also suffered from elevated clinical levels of psychiatric symptomatology, including anxiety, depression and phobic avoidance, and neurological symptoms of tremor, weakness in the limbs, and excessive sweating. CONCLUSIONS: The exposed group suffered from varying degrees of permanent neuropsychological disability, which adversely affects their ability to work and be financially independent. Psychometric measures for monitoring cognitive symptoms are discussed.

L6 ANSWER 2 OF 17 MEDLINE
 ACCESSION NUMBER: 2000392640 MEDLINE
 DOCUMENT NUMBER: 20287784 PubMed ID: 10828116
 TITLE: Psychiatrists' referrals to self-help groups for people with mood disorders.
 AUTHOR: Powell T J; Silk K R; Albeck J H
 CORPORATE SOURCE: School of Social Work, University of Michigan, Ann Arbor, MI 48109-1106, USA.. tpowell@umich.edu
 CONTRACT NUMBER: MH46399 (NIMH)
 SOURCE: PSYCHIATRIC SERVICES, (2000 Jun) 51 (6) 809-11.
 Journal code: 9502838. ISSN: 1075-2730.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200008
 ENTRY DATE: Entered STN: 20000824
 Last Updated on STN: 20000824
 Entered Medline: 20000817

AB The study examined psychiatrists' referrals to and support for participation in self-help groups by people with mood disorders. Massachusetts and Michigan psychiatrists with a special interest in patients with mood disorders were surveyed; the 278 respondents represented a 78 percent response rate. About three-fourths of the psychiatrists reported that they made referrals to and felt knowledgeable about self-help groups. However, less than half had self-help literature available or discussed self-help groups with their patients. Beliefs that a patient would gain a better understanding of the illness and would receive support after an episode of illness were positively related to support for self-help. Beliefs that the program was inappropriate and that it lacked professional oversight were negatively related.

L6 ANSWER 3 OF 17 MEDLINE
 ACCESSION NUMBER: 2000130287 MEDLINE
 DOCUMENT NUMBER: 20130287 PubMed ID: 10662789
 TITLE: A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes.
 COMMENT: Comment in: J Exp Med. 2000 Feb 7;191(3):411-6
 AUTHOR: Huang F P; Platt N; Wykes M; Major J R; Powell T J
 ; Jenkins C D; MacPherson G G

CORPORATE SOURCE: Sir William Dunn School of Pathology, University of Oxford,

Oxford OX1 3RE, United Kingdom.

SOURCE: JOURNAL OF EXPERIMENTAL MEDICINE, (2000 Feb 7) 191 (3) 435-44.

Journal code: 2985109R. ISSN: 0022-1007.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200004

ENTRY DATE: Entered STN: 20000427

Last Updated on STN: 20021231

Entered Medline: 20000418

AB This study identifies a dendritic cell (DC) subset that constitutively transports apoptotic intestinal epithelial cell remnants to T cell areas of mesenteric lymph nodes in vivo. Rat intestinal lymph contains two DC populations. Both populations have typical DC morphology, are major histocompatibility complex class II(hi), and express OX62, CD11c, and B7. CD4(+)/OX41(+) DCs are strong antigen-presenting cells (APCs).

CD4(-)/OX41(-) DCs are weak APCs and contain cytoplasmic apoptotic DNA, epithelial cell-restricted cytokeratins, and nonspecific esterase (NSE) (+)

inclusions, not seen in OX41(+) DCs. Identical patterns of NSE electrophoretic variants exist in CD4(-)/OX41(-) DCs, intestinal epithelial cells, and mesenteric node DCs but not in other DC

populations, macrophages, or tissues. Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL)-positive DCs and strongly NSE(+) DCs

are present in intestinal lamina propria. Peyer's patches and mesenteric but not other lymph nodes contain many strongly NSE(+) DCs in interfollicular and T cell areas. Similar DCs are seen in the ileum and

in T cell areas of mesenteric nodes in gnotobiotic rats. These results show that a distinct DC subset constitutively endocytoses and transports apoptotic cells to T cell areas and suggest a role for these DCs in inducing and maintaining peripheral self-tolerance.

L6 ANSWER 4 OF 17 MEDLINE

ACCESSION NUMBER: 2000108988 MEDLINE

DOCUMENT NUMBER: 20108988 PubMed ID: 10641012

TITLE: Derivation of temporary emergency exposure limits (TEELs).

AUTHOR: Craig D K; Davis J S; Hansen D J; Petrocchi A J; Powell T J; Tuccinardi T E Jr

CORPORATE SOURCE: Westinghouse Safety Management Solutions, Inc., Aiken, SC 29803, USA.

SOURCE: JOURNAL OF APPLIED TOXICOLOGY, (2000 Jan-Feb) 20 (1) 11-20.

Journal code: 8109495. ISSN: 0260-437X.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200003

ENTRY DATE: Entered STN: 20000407

Last Updated on STN: 20000407

Entered Medline: 20000324

AB Short-term chemical concentration limits are used in a variety of

applications, including emergency planning and response, hazard assessment and safety analysis. Development of emergency response planning guidelines (ERPGs) and acute exposure guidance levels (AEGLs) are predicated on this need. Unfortunately, the development of peer-reviewed community exposure limits for emergency planning cannot be done rapidly (relatively few ERPGs or AEGLs are published each year). To be protective of Department of Energy (DOE) workers, on-site personnel and the adjacent general public, the DOE Subcommittee on Consequence Assessment and Protective Actions (SCAPA) has developed a methodology for deriving temporary emergency exposure limits (TEELs) to serve as temporary guidance until ERPGs or AEGLs can be developed. These TEELs are approximations to ERPGs to be used until peer-reviewed toxicology-based ERPGs, AEGL or equivalents can be developed. Originally, the TEEL method used only hierarchies of published concentration limits (e.g. PEL- or TLV-TWAs, -STELs or -Cs, and IDLHs) to provide estimated values approximating ERPGs. Published toxicity data (e.g. lc(50), lc(LO), ld(50) and ld(LO) for TEEL-3, and tc(LO) and td(LO) for TEEL-2) are included in the expanded method for deriving TEELs presented in this paper. The addition here of published toxicity data (in addition to the exposure limit hierarchy) enables TEELs to be developed for a much wider range of chemicals than before. Hierarchy-based values take precedence over toxicity-based values, and human toxicity data are used in preference to animal toxicity data. Subsequently, default assumptions based on statistical correlations of ERPGs at different levels (e.g. ratios of ERPG-3s to ERPG-2s) are used to calculate TEELs where there are gaps in the data. Most required input data are available in the literature and on CD ROMs, so the required TEELs for a new chemical can be developed quickly. The new TEEL hierarchy/toxicity methodology has been used to develop community exposure limits for over 1200 chemicals to date. The new TEEL methodology enables emergency planners to develop useful approximations to peer-reviewed community exposure limits (such as the ERPGs) with a high degree of confidence. For definitions and acronyms, see Appendix.

Copyright 2000 Westinghouse Safety Management Solutions LLC obtained pursuant to US government contract.

L6 ANSWER 5 OF 17 MEDLINE
ACCESSION NUMBER: 2000050243 MEDLINE
DOCUMENT NUMBER: 20050243 PubMed ID: 10583160
TITLE: Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors.
AUTHOR: Powell T J; Ben-Bassat H; Klein B Y; Chen H; Shenoy N; McCollough J; Narog B; Gazit A; Harzstark Z; Chaouat M; Levitzki R; Tang C; McMahon J; Shawver L; Levitzki A
CORPORATE SOURCE: SUGEN, Inc; Redwood City, CA 94063, USA.
SOURCE: BRITISH JOURNAL OF DERMATOLOGY, (1999 Nov) 141 (5) 802-10.
Journal code: 0004041. ISSN: 0007-0963.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English

FILE SEGMENT: Priority Journals
ENTRY MONTH: 200005
ENTRY DATE: Entered STN: 20000512
Last Updated on STN: 20000512
Entered Medline: 20000502

AB Psoriasis is characterized by hyperproliferation of keratinocytes associated with an inflammatory infiltrate in the epidermis. Among factors which may be related to hyperplasia of psoriatic keratinocytes is the persistent autocrine stimulation of the epidermal growth factor receptor (EGFR) by transforming growth factor-alpha. Owing to the pivotal role of the EGFR in driving the growth of human psoriatic keratinocytes, we examined two selective inhibitors of EGFR kinase activity: 4-(3-bromophenylamino)-6, 7-dimethoxyquinazoline (AG1517/SU5271) and 4-(3-chlorophenylamino)-6, 7-dimethoxyquinazoline (AG1478) on psoriatic keratinocytes. SU5271 potentially inhibits ligand-induced autophosphorylation of EGFR, and downstream signal transduction events, including DNA replication and cell cycle progression. SU5271, at micromolar concentrations, inhibited the proliferation of keratinocytes isolated from psoriatic lesions in excellent correlation with its EGFR kinase inhibitory activity in these cells. Biologically active concentrations of SU5271 penetrated human cadaver skin, suggesting that this compound is a strong candidate as an antipsoriatic agent.

L6 ANSWER 6 OF 17 MEDLINE
ACCESSION NUMBER: 1999440218 MEDLINE
DOCUMENT NUMBER: 99440218 PubMed ID: 10510523
TITLE: Recommended default methodology for analysis of airborne exposures to mixtures of chemicals in emergencies.
AUTHOR: Craig D K; Baskett R L; Davis J S; Dukes L; Hansen D J; Petrocchi A J; **Powell T J**; Sutherland P J; Tuccinardi T E Jr
CORPORATE SOURCE: Westinghouse Safety Management Solutions LLC, Aiken, South Carolina, USA.
SOURCE: APPLIED OCCUPATIONAL AND ENVIRONMENTAL HYGIENE, (1999 Sep) 14 (9) 609-17. Ref: 11
Journal code: 9103256. ISSN: 1047-322X.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199910
ENTRY DATE: Entered STN: 20000111
Last Updated on STN: 20000111
Entered Medline: 19991022

AB Emergency planning and hazard assessment of Department of Energy (DOE) facilities require consideration of potential exposures to mixtures of chemicals released to the atmosphere. Exposure to chemical mixtures may lead to additive, synergistic, or antagonistic health effects. In the past, the consequences of exposures to each chemical have been analyzed separately. This approach may not adequately protect the health of persons exposed to mixtures. This article presents default recommendations for use in emergency management and safety analysis within the DOE complex where

potential exists for releases of mixtures of chemicals. These recommendations were developed by the DOE Subcommittee on Consequence Assessment and Protective Actions (SCAPA). It is recommended that hazard indices (e.g., $HII = C_i / Limit_i$, where C_i is the concentration of chemical "i") be calculated for each chemical, and unless sufficient toxicological knowledge is available to indicate otherwise, that they be summed, that is, $\sum_i HII_i = HII_1 + HII_2 + \dots + HII_n$. A sum of 1.0 or less means the limits have not been exceeded. To facilitate application of these recommendations for analysis of exposures to specific mixtures, chemicals are classified according to their toxic consequences. This is done using health code numbers describing toxic effects by target organ for each chemical. This methodology has been applied to several potential releases of chemicals to compare the resulting hazard indices of a chemical

mixture

with those obtained when each chemical is treated independently. The methodology used and results obtained from analysis of one mixture are presented in this article. This article also demonstrates how health code numbers can be used to sum hazard indices only for those chemicals that have the same toxic consequence.

L6 ANSWER 7 OF 17 MEDLINE
 ACCESSION NUMBER: 1999372831 MEDLINE
 DOCUMENT NUMBER: 99372831 PubMed ID: 10445659
 TITLE: Attitudes of AA contact persons toward group participation by persons with a mental illness.
 AUTHOR: Meissen G; Powell T J; Wituk S A; Girrens K; Arteaga S
 CORPORATE SOURCE: Department of Psychology, Wichita State University, Kansas 67260, USA.. meissen@twsu.edu
 SOURCE: PSYCHIATRIC SERVICES, (1999 Aug) 50 (8) 1079-81. Journal code: 9502838. ISSN: 1075-2730.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199909
 ENTRY DATE: Entered STN: 19990925
 Last Updated on STN: 19990925
 Entered Medline: 19990910

AB Alcoholics Anonymous groups are underused by persons with the dual diagnoses of mental illness and substance use disorder, and mental health professionals are cautious about referring them to AA because of fears that the AA group will discourage them from taking prescribed medication. The study assessed the attitudes of 125 AA contact persons about the participation of persons with mental illness. The majority had positive attitudes toward such persons, and 93 percent indicated that they should continue taking their medication. Fifty-four percent felt that participation in a group especially for persons with a dual diagnosis would be more desirable than in a traditional AA group. However, such groups are often not available.

L6 ANSWER 8 OF 17 MEDLINE
 ACCESSION NUMBER: 1999111045 MEDLINE
 DOCUMENT NUMBER: 99111045 PubMed ID: 9815796
 TITLE: Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
 AUTHOR: Shawver L K; Schwartz D P; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs J S;

Tang C; Ullrich A; Berens M E; Hersh E; McMahon G; Hirth K
P; **Powell T J**
CORPORATE SOURCE: SUGEN, Inc., Redwood City, California 94063, USA.
SOURCE: CLINICAL CANCER RESEARCH, (1997 Jul) 3 (7)
1167-77.
Journal code: 9502500. ISSN: 1078-0432.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199902
ENTRY DATE: Entered STN: 19990311
Last Updated on STN: 20000303
Entered Medline: 19990225

AB Many reports have cited coexpression of platelet-derived growth factor (PDGF) and its receptors by tumor cells or cells supporting tumor growth, suggesting both autocrine and paracrine mechanisms for PDGF-mediated tumor growth. We found that a small organic molecule, N-[4-(trifluoromethyl)phenyl] 5-methylisoxazole-4-carboxamide (SU101, leflunomide), inhibited PDGF-mediated signaling events, including receptor tyrosine phosphorylation, DNA synthesis, cell cycle progression, and cell proliferation. SU101 inhibited PDGF-stimulated tyrosine phosphorylation of PDGF receptor (PDGFR) beta in C6 (rat glioma) and NIH3T3 cells engineered to overexpress human PDGFRbeta (3T3-PDGFRbeta). SU101 blocked both PDGF- and epidermal growth factor (EGF)-stimulated DNA synthesis. Previously, this compound was shown to inhibit pyrimidine biosynthesis by interfering with the enzymatic activity of dihydroorotate dehydrogenase. In the current study, EGF-stimulated DNA synthesis was restored by the addition of saturating quantities of uridine, whereas PDGF-induced DNA synthesis was not, suggesting that the compound demonstrated some selectivity for the PDGFR pathway that was independent of pyrimidine biosynthesis. Selectivity was further demonstrated by the ability of the compound to block the entry of PDGF-stimulated cells into the S phase of the cell cycle, without affecting cell cycle progression of EGF-stimulated cells. In cell growth assays, SU101 selectively inhibited the growth of PDGFRbeta-expressing cell lines more efficiently than it inhibited the growth of PDGFRbeta-negative cell lines. SU101 inhibited the s.c., i.p., and intracerebral growth of a panel of cell lines including cells from glioma, ovarian, and prostate origin. In contrast, SU101 failed to inhibit the in vitro or s.c. growth of A431 and KB tumor cells, both of which express EGF receptor but not PDGFRbeta. SU101 also inhibited the growth of D1B and L1210 (murine leukemia) cells in syngeneic immunocompetent mice, without causing adverse effects on the immune response of the animals. In an i.p. model of tumor growth in syngeneic immunocompetent mice, SU101 prevented tumor growth and induced long-term survivors in animals implanted with 7TD1 (murine B-cell hybridoma) tumor cells. Because PDGFRbeta was detected on most of the tumor cell lines in which in vivo growth was inhibited by SU101, these data suggest that SU101 is an effective inhibitor of PDGF-driven tumor growth in vivo.

L6 ANSWER 9 OF 17 MEDLINE
ACCESSION NUMBER: 1999107211 MEDLINE
DOCUMENT NUMBER: 99107211 PubMed ID: 9892193
TITLE: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that

inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

AUTHOR: Fong T A; Shawver L K; Sun L; Tang C; App H; **Powell T J**; Kim Y H; Schreck R; Wang X; Risau W; Ullrich A; Hirth K P; McMahon G

CORPORATE SOURCE: SUGEN, Inc., South San Francisco, California 94080, USA.. fong@progenitor.com

SOURCE: CANCER RESEARCH, (1999 Jan 1) 59 (1) 99-106.
Journal code: 2984705R. ISSN: 0008-5472.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199902

ENTRY DATE: Entered STN: 19990216
Last Updated on STN: 20000303
Entered Medline: 19990204

AB SU5416, a novel synthetic compound, is a potent and selective inhibitor of the Flk-1/KDR receptor tyrosine kinase that is presently under evaluation in Phase I clinical studies for the treatment of human cancers. SU5416 was shown to inhibit vascular endothelial growth factor-dependent mitogenesis of human endothelial cells without inhibiting the growth of a variety of tumor cells in vitro. In contrast, systemic administration of SU5416 at nontoxic doses in mice resulted in inhibition of subcutaneous tumor growth of cells derived from various tissue origins. The antitumor effect of SU5416 was accompanied by the appearance of pale white tumors that were resected from drug-treated animals, supporting the antiangiogenic property of this agent. These findings support that pharmacological inhibition of the enzymatic activity of the vascular endothelial growth factor receptor represents a novel strategy for limiting the growth of a wide variety of tumor types.

L6 ANSWER 10 OF 17 MEDLINE

ACCESSION NUMBER: 96317074 MEDLINE

DOCUMENT NUMBER: 96317074 PubMed ID: 8743300

TITLE: A follow-up study of patients hospitalized after minor head injury.

AUTHOR: **Powell T J**; Collin C; Sutton K

CORPORATE SOURCE: Psychology Department, Erleigh Road Clinic, Reading, UK.

SOURCE: DISABILITY AND REHABILITATION, (1996 May) 18 (5) 231-7.
Journal code: 9207179. ISSN: 0963-8288.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199610

ENTRY DATE: Entered STN: 19961025
Last Updated on STN: 20000303
Entered Medline: 19961016

AB Minor head injury accounts for 95% of all head injury. In this study 62 patients, hospitalized after minor head injury, were assessed within 48 h, and invited to attend for review and retesting 3 months later. Thirty-five

patients were followed up in this way and 11 more were interviewed over the telephone. There was significant improvement on all psychometric tests

between initial evaluation and follow-up. Between 51% and 86% reported troublesome late post-concussional symptoms, of which headaches and tiredness were the most frequently reported symptoms. Length of post-traumatic amnesia (PTA) was related to severity of symptoms.

Clinical

levels of anxiety and stress were noted in approximately one-third of the whole group; 95% of the group had returned to work by 3 months with a mean absence rate of 9.4 days. The therapeutic implications of these results are discussed.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.90

40.99

STN INTERNATIONAL LOGOFF AT 11:54:22 ON 18 MAR 2003